Kura Oncology, Inc. - KURA STOCK NEWS

Kura Oncology (Nasdaq: KURA) has announced the publication of its KOMET-001 Phase 1 study results for ziftomenib in The Lancet Oncology. The study evaluated the safety, tolerability, and clinical activity of ziftomenib in relapsed/refractory acute myeloid leukemia (AML). Key findings include:

1. Promising clinical activity with manageable toxicity in heavily pretreated patients.
2. Marrow blast reduction, neutrophil and platelet recovery, transfusion independence, and clearance of measurable residual disease.
3. Determination of the recommended phase 2 dose (RP2D).

The company has completed enrollment for the Phase 2 portion of KOMET-001, a registration-directed trial in patients with NPM1-mutant AML. Topline data from this trial is expected in early 2025.

Kura Oncology (Nasdaq: KURA) has appointed Michael Vasconcelles, M.D., to its Board of Directors. Dr. Vasconcelles brings over 25 years of oncology drug development experience to the clinical-stage biopharmaceutical company. He currently serves as a Senior Advisor at Frazier Healthcare Partners and has held executive positions at ImmunoGen, Flatiron Health, Unum Therapeutics, Takeda/Millennium, Genzyme, and Sanofi Oncology.

The appointment comes at a key inflection point for Kura Oncology as it advances its menin inhibitor and farnesyl transferase inhibitor (FTI) programs for cancer treatment. Dr. Vasconcelles' expertise in R&D, regulatory affairs, and leadership across various companies is expected to be valuable in progressing these therapies through clinical trials and towards commercialization.

Kura Oncology (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment, has announced its participation in the upcoming Cantor Global Healthcare Conference in New York. The company's President and CEO, Troy Wilson, Ph.D., J.D., is set to take part in a fireside chat on September 17, 2024, at 1:20 p.m. ET / 10:20 a.m. PT.

Interested parties can access a live audio webcast of the fireside chat through the investor section of Kura's website at www.kuraoncology.com. An archived replay will also be available after the live event concludes. This conference participation provides an opportunity for Kura Oncology to showcase its progress and engage with the healthcare investment community.

Kura Oncology (Nasdaq: KURA) reported Q2 2024 financial results and provided a corporate update. Key highlights:

• Completed enrollment in KOMET-001 trial of ziftomenib in R/R NPM1-mutant AML; topline data expected in early 2025
• Received Breakthrough Therapy Designation for ziftomenib in R/R NPM1-mutant AML
• Phase 1b expansion study of ziftomenib combinations now enrolling
• IND cleared for ziftomenib in GIST; proof-of-concept study to begin in early 2025
• First patient dosed in KO-2806 and adagrasib combination study in NSCLC
• $491.5 million cash runway into 2027

Q2 2024 financials: R&D expenses $39.7M, G&A expenses $16.7M, net loss $50.8M

Kura Oncology (Nasdaq: KURA) announced FDA clearance of an IND application for ziftomenib, their menin inhibitor, to treat advanced gastrointestinal stromal tumors (GIST). A Phase 1 study combining ziftomenib with imatinib is planned for early 2025. Preclinical data suggest this combination could resensitize patients to imatinib and induce durable responses in imatinib-resistant cases. GIST, the most common sarcoma, is typically treated with KIT inhibitors like imatinib. However, many patients develop resistance, limiting treatment options. Ziftomenib targets the menin-MLL complex, which regulates KIT expression in GIST cells. This marks the first IND clearance for a menin inhibitor in GIST treatment, potentially offering a new approach for patients with options.

Kura Oncology (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment, has announced it will release its second quarter 2024 financial results on Thursday, August 8, 2024, after U.S. financial markets close. The company's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT on the same day to discuss the financial results and provide a corporate update.

Interested parties can access the live call by dialing (877) 300-8521 (domestic) or (412) 317-6026 (international). A live webcast and archived replay of the event will be available on the company's website at www.kuraoncology.com in the investor relations section.

Kura Oncology, a clinical-stage biopharmaceutical company, announced the issuance of inducement grants under Nasdaq Listing Rule 5635(c)(4) on July 1, 2024. The Compensation Committee granted nonstatutory stock options to purchase 128,700 shares of common stock to eight new employees under the 2023 Inducement Option Plan. These options have an exercise price of $21.20 per share, matching the closing sales price on the grant date. The options will vest over four years, with 25% vesting after one year and the remainder monthly over the following 36 months, subject to continuous service.

Kura Oncology has presented preclinical data showing the potential of menin inhibitors, specifically ziftomenib, in treating type 2 diabetes. The findings, shared at the American Diabetes Association’s 84th Scientific Sessions, highlight ziftomenib's ability to enhance pancreatic function, boost insulin production, and improve insulin sensitivity in preclinical models. Notably, the therapeutic effects persisted even after stopping the dose, indicating a possible restoration of beta-cell mass. Kura is also developing next-generation menin inhibitors targeting diabetes and other metabolic diseases, in addition to its ongoing clinical trials in acute leukemias.

Kura Oncology announced the granting of inducement awards under Nasdaq Listing Rule 5635(c)(4). On June 3, 2024, the Compensation Committee awarded nonstatutory stock options to purchase 152,500 shares of common stock to eight new employees under the 2023 Inducement Option Plan. The exercise price for each option is $21.19 per share, matching the closing sales price on the grant date. The options vest over four years—25% after one year and the remainder monthly over the next 36 months, contingent on continued employment. These inducement awards aim to attract and retain talent effectively.